Gastrointestinal Bleeding Treatment Market Size, Share & Trends Analysis: Global Industry Size Is Predicted to Grow USD 1092 Million by 2030, at a CAGR of likely 4.56%

As per Facts and Factors study, the global gastrointestinal bleeding treatment market size was worth around USD 732 million in 2021 and is predicted to grow to around USD 1092 million by 2030 with a compound annual growth rate (CAGR) of roughly 4.56% between 2022 and 2030.

Report Link with All Related Graphs & Charts: https://www.fnfresearch.com/gastrointestinal-bleeding-treatment-market

Gastrointestinal Bleeding Treatment Market: Overview

Gastrointestinal bleeding is a symptom associated with digestive tract disorder. The blood, as a consequence of the condition, generally appears in vomit or stool but it may not be visible when appearing with the latter as the stool color may change to tarry or black. The blood flow intensity can vary from mild to severe and in certain cases, it is life-threatening. To effectively locate the bleeding cause, sophisticated imaging tools are required and the treatment will depend on the bleeding source. The signs of the condition can either be hidden or obvious and they are dependent on the exact location the bleeding is occurring from.

Obvious bleeding is called overt bleeding and it may show up as vomit blood that is generally dark brown or red. It may also be as black or tarry stool or in the form of rectal bleeding. In the case of hidden bleeding, called occult bleeding, the associated symptoms include chest pain, difficulty in breathing, lightheadedness, fainting, and abdominal pain. A patient suffering from gastrointestinal (GI) bleeding may go into shock if the bleeding starts suddenly or the rate of flow increases abruptly. There are certain symptoms that are related to shock and include rapid pulse, drop in blood pressure, and unconsciousness amongst others.

Get a Free Sample Report with All Related Graphs & Charts (with COVID 19 Impact Analysis): https://www.fnfresearch.com/sample/gastrointestinal-bleeding-treatment-market

Key Insights:

  • As per the analysis shared by our research analyst, the global gastrointestinal bleeding treatment market is estimated to grow annually at a CAGR of around 4.56% over the forecast period (2022-2030)
  • In terms of revenue, the global gastrointestinal bleeding treatment market size was valued at around USD 732 million in 2021 and is projected to reach USD 1092 million, by 2030.
  • The market is projected to grow at a significant rate due to the growing population suffering from GI bleeding-inducing diseases
  • Based on gastrointestinal (GI) tract division segmentation, upper GI was predicted to show maximum market share in the year 2021
  • Based on product segmentation, endoscopic hemostatic devices were the leading product in 2021
  • On the basis of region, North America was the leading revenue generator in 2021

Facts and Factors published the latest report titled “Gastrointestinal Bleeding Treatment Market Size, Share, Growth Analysis Report By Gastrointestinal (GI) Tract Division (Lower GI and Upper GI), By Product (Closure Devices and Endoscopic Hemostatic Devices), and By Region – Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2030into their research database.

Industry Dynamics:

Global Gastrointestinal Bleeding Treatment Market: Growth Drivers

  • Growing population suffering from GI bleeding-inducing diseases to propel market demand.

The global gastrointestinal bleeding treatment market is projected to grow owing to the increasing number of patients who are suffering from diseases that can cause GI bleeding. GI is not a disease in itself but one of the symptoms associated with several diseases. Some of them include ulcerative colitis, peptic ulcers, hemorrhoids, inflammation of the esophagus, colon, stomach, or esophagus cancer, and Crohn’s disease. As the cause of GI bleeding can be any of the mentioned diseases, the number of patients with the issue remains consistently high.

Crohn’s disease remains one of the leading causes of gastrointestinal bleeding. It is an inflammatory bowel disease (IBD) that leads to swelling of the digestive tract tissue. It can cause weight loss leading up to malnutrition or severe abdominal pain. In certain situations, Crohn’s disease can be life-threatening. Currently, there is no cure for the disease but therapies can help patients manage the condition and symptoms. With enough and effective treatment, many patients have reported being functional well. As per official data, upper GI bleeding is observed in almost 50 to 150 out of 100,00 adults annually. More than 100,000 people in the US reportedly visit hospitals to get GI bleeding treatment.

Global Gastrointestinal Bleeding Treatment Market: Restraints

  • Uncertainty related to the cause of the disease to impede market expansion.

There is no one particular reason for GI bleeding to start. It can due to several factors which make the detection of the symptom extremely difficult in the medical community. Doctors and healthcare professionals have to invest in highly advanced imaging techniques to understand the main reason for the bleeding to occur which results in delayed treatment. Without the right information, doctors are unable to provide an accurate and timely cure.

Directly Purchase a Copy of the Report @ https://www.fnfresearch.com/buynow/su/gastrointestinal-bleeding-treatment-market

Gastrointestinal Bleeding Treatment Market: Opportunity

  • Increasing cases of stomach cancer to cause further growth.

One of the most common symptoms of a stomach or gastric cancer is gastrointestinal bleeding. In the majority of the cases, occult bleeding is more common as compared to overt bleeding which is observed in less than 20% of the cases. Stomach cancer occurs due to the cells that originate in the stomach. Gastric cancer may not necessarily show any initial symptoms but patients in the later stages of cancer are known to suffer from extreme weight loss, tiredness, black stools, and vomiting blood. Studies have indicated that over 7 in 100,000 people get diagnosed with stomach cancer and 0.8% of men & women may be diagnosed with the disease at some point in life.

Gastrointestinal Bleeding Treatment Market: Challenges

  • Clearing of the blood clot and blood remains a challenge in the market.

The biggest challenge that remains during the medical procedures involving the operation related to upper GI bleeding is the proper clearing of blood clots and blood to help the medical professionals clearly visualize the bleeding site. Gastric lavage is the most widely used method but it is an extremely lengthy process and sometimes it may not remove the gastric content completely.

Global Gastrointestinal Bleeding Treatment Market: Segmentation

  • The global gastrointestinal bleeding treatment market is segmented based on gastrointestinal (GI) tract division, product, and region.

Based on the gastrointestinal (GI) tract division, the global market segments are lower GI and upper GI with the latter leading the segmental growth in 2021 due to the high prevalence of the condition. One of the major reasons for upper GI tract bleeding is peptic ulcer. These are sores that originate in the inner lining of the stomach along with the upper portion of the small intestine. The sores can be caused due to stomach lining getting damaged because of stomach acid, consumption of anti-inflammatory drugs, or bacteria. The chances of a person suffering from upper GI bleeding is 70% whereas the risk percentage for lower GI bleeding is around 30%.

Based on product, the global market divisions are closure devices and endoscopic hemostatic devices with the latter leading the global market growth in the previous year and the same trend projected for the coming years. Endoscopic hemostatic is one of the most common methods of treating gastrointestinal bleeding. The procedure is critical for managing GI hemorrhage and for preventing GI bleeding during highly risky endoscopic processes. A recent study concluded the success rate of endoscopic treatment for treating peptic ulcers was around 94%.

Get More Insight before Buying@: https://www.fnfresearch.com/inquiry/gastrointestinal-bleeding-treatment-market

List of Key Players in Gastrointestinal Bleeding Treatment Market:

  • Ovesco Endoscopy AG.
  • CONMED Corporation
  • Cook Medical
  • Boston Scientific Corporation
  • Olympus Corporation
  • US Medical Innovations

Key questions answered in this report:

  • What are the growth rate forecast and market size for GASTROINTESTINAL BLEEDING TREATMENT Market?
  • What are the key driving factors propelling the GASTROINTESTINAL BLEEDING TREATMENT Market forward?
  • What are the most important companies in the GASTROINTESTINAL BLEEDING TREATMENT Market Industry?
  • What segments does the GASTROINTESTINAL BLEEDING TREATMENT Market cover?
  • How can I receive a free copy of the GASTROINTESTINAL BLEEDING TREATMENT Market sample report and company profiles?

Report Scope:

Report Attribute

Details

Market size value in 2021

USD 732 Million

Revenue forecast in 2030

USD 1,092 Million

Growth Rate

CAGR of almost 4.56 % 2023-2030

Base Year

2020

Historic Years

2016 – 2022

Forecast Years

2022 – 2030

Segments Covered

By Gastrointestinal (GI) Tract Division, Product, and Region

Forecast Units

Value (USD Billion), and Volume (Units)

Quantitative Units

Revenue in USD million/billion and CAGR from 2022 to 2030

Regions Covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World

Countries Covered

U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others

Companies Covered

Ovesco Endoscopy AG., CONMED Corporation, Cook Medical, Boston Scientific Corporation, Olympus Corporation, US Medical Innovations, and others.

Report Coverage

Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.

Customization Scope

Avail of customized purchase options to meet your exact research needs.  

https://www.fnfresearch.com/customization/gastrointestinal-bleeding-treatment-market

Free Brochure: https://www.fnfresearch.com/ask-to-analyst/gastrointestinal-bleeding-treatment-market

Regional Dominance:

  • North America to register the highest growth.

The global gastrointestinal bleeding treatment market is projected to register the highest growth in North America due to the highly advanced medical infrastructure of the US and Canada. The regional growth is likely to witness surging growth due to the rise in approvals by the US Food and Drugs Administration (FDA) authority. In 2018, the agency approved the use of a Hemospray device which is meant to treat GI bleeding conditions. The device is capable of stopping the bleeding without the use of any mechanical, thermal, or contact method that is known to cause complications if not done correctly.

Hemospray is a single-use device and it works by spraying inorganic power on the bleeding site which becomes an advantageous factor because it eliminates the need to visualize the site. Growth in Asia-Pacific may be driven by the increase in research & development of new treatment methods for GI bleeding-inducing medical diseases.

Global Gastrointestinal Bleeding Treatment Market is segmented as follows:

Gastrointestinal Bleeding Treatment Market: By Gastrointestinal (GI) Tract Division Outlook (2023-2030)

  • Lower GI
  • Upper GI

Gastrointestinal Bleeding Treatment Market: By Product Outlook (2023-2030)

  • Closure Devices
  • Endoscopic Hemostatic Devices

Gastrointestinal Bleeding Treatment Market: By Region Outlook (2023-2030)

North America

  • The U.S.
  • Canada

Europe

  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC
  • South Africa
  • Rest of Middle East & Africa

Press Release: https://www.fnfresearch.com/news/global-gastrointestinal-bleeding-treatment-market

Browse Other Related Research Reports from Facts and Factors

  • Active Wound Care Market: According to the report published by Facts and Factors, the global active wound care market size was worth around USD 9.35 billion in 2022 and is predicted to grow to around USD 14.2 billion by 2030 with a compound annual growth rate (CAGR) of roughly 5.61% between 2023 and 2030.
  • MRI Contrast Media Agents Market: According to the report published by Facts and Factors, the global MRI contrast media agents market size was worth around USD 2.0 billion in 2022 and is predicted to grow to around USD 3.2 billion by 2030 with a compound annual growth rate (CAGR) of roughly 6.1% between 2023 and 2030.
  • Blood Clot Retrieval Devices Market: According to the report published by Facts and Factors, the global blood clot retrieval devices market size was worth around USD 1.6 billion in 2022 and is predicted to grow to around USD 5.0 billion by 2030 with a compound annual growth rate (CAGR) of roughly 15.2% between 2023 and 2030.
  • Respiratory Diagnostics Market: According to the report published by Facts and Factors, the global respiratory diagnostics market size was worth around USD 8.21 billion in 2021 and is predicted to grow to around USD 13.81 billion by 2030 with a compound annual growth rate (CAGR) of roughly 9.12% between 2022 and 2030.
  • Orthopedic Prosthetic Market: According to the report published by Facts & Factors, the global orthopedic prosthetic market size was worth around USD 2.3 billion in 2022 and is predicted to grow to around USD 3.4 billion by 2030 with a compound annual growth rate (CAGR) of roughly 5.31% between 2023 and 2030.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version